As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

The findings highlight the need for public-health strategies aimed at mitigating dementia risk and promoting healthy aging across diverse populations, researchers said. “I think ...

Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

The study also integrates drug databases ... New Brain Mapping ... brain that are hallmarks of Alzheimer's disease up to 20 years before the earliest symptoms of dementia ...

19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease ... dementia, according to a new ...

A new study finds that dementia cases will increase at a much higher rate than expected, with lifetime risk rising to 42 ...

CMS will promote the approval of ZUNVEYL in China as soon as possible to bring a new drug option for the treatment of cognitive impairment in Alzheimer’s disease patients. ZUNVEYL was approved ...